Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is Still On The Mark Following 26% Share Price Bounce

Simply Wall StNov 7 06:47 ET

Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%

BenzingaNov 5 12:10 ET

Intra-Cellular Meets Main Goal in Late Stage Trial for Its Schizophrenia Treatment

Seeking AlphaNov 5 08:53 ET

Express News | Intra-Cellular Therapies Inc - Primary Endpoint Shows Longer Time to Relapse With Lumateperone

ReutersNov 5 07:00 ET

Express News | Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating Caplyta for the Prevention of Relapse in Patients With Schizophrenia

ReutersNov 5 07:00 ET

Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews

BenzingaNov 4 11:00 ET